William Blair Issues Positive Forecast for ResMed Earnings

ResMed Inc. (NYSE:RMD) – William Blair increased their Q3 2025 earnings per share (EPS) estimates for ResMed in a research report issued on Friday, December 6th. William Blair analyst M. Andrew now anticipates that the medical equipment provider will post earnings of $2.37 per share for the quarter, up from their previous forecast of $2.33. The consensus estimate for ResMed’s current full-year earnings is $9.28 per share. William Blair also issued estimates for ResMed’s Q4 2025 earnings at $2.44 EPS and FY2025 earnings at $9.30 EPS.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The business had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the previous year, the firm posted $1.64 earnings per share. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis.

A number of other equities research analysts have also issued reports on the stock. Wolfe Research reissued an “underperform” rating and issued a $180.00 price target on shares of ResMed in a report on Wednesday, September 18th. Baird R W upgraded ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a report on Friday, October 25th. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Finally, Bank of America raised their price target on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, ResMed presently has an average rating of “Moderate Buy” and an average price target of $225.70.

ResMed Trading Up 0.8 %

Shares of RMD stock opened at $241.41 on Monday. The stock has a market capitalization of $35.44 billion, a PE ratio of 31.97, a P/E/G ratio of 1.79 and a beta of 0.68. ResMed has a 1-year low of $162.05 and a 1-year high of $260.49. The business has a 50-day moving average of $242.30 and a 200 day moving average of $226.57. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91.

Institutional Investors Weigh In On ResMed

Several hedge funds and other institutional investors have recently modified their holdings of RMD. State Street Corp raised its stake in ResMed by 1.9% during the 3rd quarter. State Street Corp now owns 6,261,633 shares of the medical equipment provider’s stock worth $1,528,590,000 after acquiring an additional 116,918 shares during the period. Bank of New York Mellon Corp increased its stake in shares of ResMed by 51.4% in the second quarter. Bank of New York Mellon Corp now owns 5,772,761 shares of the medical equipment provider’s stock worth $1,105,022,000 after purchasing an additional 1,959,642 shares in the last quarter. Geode Capital Management LLC raised its position in shares of ResMed by 10.9% during the 3rd quarter. Geode Capital Management LLC now owns 3,858,814 shares of the medical equipment provider’s stock valued at $939,114,000 after purchasing an additional 380,383 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of ResMed by 1.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 924,047 shares of the medical equipment provider’s stock valued at $225,578,000 after buying an additional 13,985 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in ResMed by 0.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 742,411 shares of the medical equipment provider’s stock worth $181,237,000 after buying an additional 2,406 shares during the period. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other ResMed news, insider Kaushik Ghoshal sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the completion of the sale, the insider now directly owns 21,788 shares of the company’s stock, valued at approximately $5,502,777.28. This represents a 18.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total transaction of $491,300.00. Following the transaction, the director now owns 81,218 shares in the company, valued at $19,951,201.70. This represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,725 shares of company stock valued at $12,516,248. Company insiders own 0.71% of the company’s stock.

ResMed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 0.88%. The ex-dividend date is Thursday, November 7th. ResMed’s dividend payout ratio is currently 28.08%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.